Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 3/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | PRKACG | P22612 | 1/20 | 0.31 |
| ▸ | PRKACB | P22694 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744027 | 0.77 | CYP1A2 (0.36) | CDK2CYP1A2CDK1 | |
| SCHEMBL18464405 | 0.65 | TSHR (0.50) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| SCHEMBL2027216 | 0.63 | CDK2 (0.63) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| SCHEMBL16146594 | 0.60 | TSHR (0.52) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| SCHEMBL16146228 | 0.60 | TSHR (0.52) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| Indole SCHEMBL8056227 | 0.59 | CYP1A2 (0.45) | CDK2CYP1A2CDK1PRKACA | |
| SCHEMBL16146186 | 0.58 | TSHR (0.53) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| SCHEMBL16146304 | 0.58 | TSHR (0.53) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| Adenine SCHEMBL9737077 | 0.58 | CDK2 (0.56) | CDK2CYP1A2CDK1PRKACACCNA2 | |
| SCHEMBL5744033 | 0.58 | CYP1A2 (0.44) | CDK2CYP1A2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | claimed |
| EP-0896063-B9 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| EP-0896063-B1 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| EP-0601092-B2 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SYNGENTA PARTICIPATIONS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-5994629-A | Positive selection | NOVARTIS AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0601092-B1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | NOVARTIS AG (CH) | 1999-07-07 | — | — | EP | disclosed |
| EP-0896063-A2 | Method for the selection of genetically transformed cells and compounds for use in the method | Novartis AG (CH) | 1999-02-10 | — | — | EP | disclosed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | disclosed |